The Waltham, Mass.-based company said that in the additional closing, it floated 3.5 million shares of its stock at a price of approximately $1.38 per share.
The placement included participation from Hudson Executive Capital and Biostar Ventures, with funds slated to support general corporate purposes, according to a press release.
With the additional $4.8 million, the company said it raised a total of $19.5 million.
Last month, Corindus Vascular Robotics announced an initial closure of the round with $15 million raised.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.